Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group. En savoir plus sur Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. En savoir plus sur Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.